Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis.

Type of Molecule

Small Molecule

Target

JAK1

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Rheumatoid Arthritis (RA) New Indication Phase 3
Crohn's Disease (CD) New Indication Phase 2
Ulcerative Colitis New Indication Phase 2
Atopic Dermatitis New Indication Phase 2
Psoriatic Arthritis New Indication Phase 3